Cardiac b-adrenergic receptor (bAR) signalling is susceptible to heterologous desensitization by different neurohormonal stimuli in clinical conditions associated with heart failure. We aim to examine the underlying mechanism of cross talk between bARs and a set of G-protein coupled receptors (GPCRs) activated by hormones/agonists. 
Introduction
b-adrenergic receptor (bAR) signal acts as a linchpin of cardiac regulation under stress. Over the last decades, homologous desensitization of bARs has been extensively studied, which has revealed essential roles of G protein receptor kinases (GRKs) and b-arrestins in inhibiting the coupling of bARs to their G proteins as well as removing bARs from the cell surface for termination of cyclic adenosine monophosphate (cAMP) generation. This paradigm has served as a cornerstone to understand bAR turn-off mechanism, which protects the heart from excessive or repetitive stimuli. 1 Meanwhile, in clinical conditions, a variety of elevated neurohormonal stimuli can impair heart contractile function via interaction with cardiac bAR signal. This phenomenon is mainly attributed to heterologous desensitization of bARs, in which bARs are phosphorylated through other pathways [such as activation of protein kinase A (PKA), and protein kinase C (PKC)] in a bAR agonistindependent manner. 1 ,2 Yet, the mechanisms underlying cross talk between cardiac bAR signal and these neurohormonal stimuli are not completely understood. GPCRs usually possess multiple phosphorylation sites (serine, threonine, and tyrosine) on their intracellular domains. In the classical paradigm, the second messenger cAMP and diacylglycerol induced by other GPCRs leads to activation of PKA and PKC, respectively, which phosphorylate serine and threonine residues on the GPCR intracellular domains. The phosphorylation also contributes to a process known as heterologous desensitization or 'non-agonist-specific' desensitization. [3] [4] [5] The phosphorylation event leads to a reduction in receptor-G-protein coupling, 6 thus attenuating the effector-mediated production of secondary messengers for downstream cellular responses. Meanwhile, other mechanism such as enhancing cAMP degradation by PKA-or CaMKIImediated activation or recruitment of phosphodiesterase (PDE) is lately discovered and added into the portrait of receptor heterologous desensitization system. [7] [8] [9] [10] [11] b-arrestins play two important roles in GPCR homologous desensitization ('agonist-specific' desensitization). First, b-arrestins bind to GRK phosphorylated receptors to interfere with G protein coupling and initiate endocytosis through clathrin-coated vesicles 12 ; Second, b-arrestins act as a scaffold protein for various other signalling molecules such as PDE to further diminish bAR-induced cAMP signal. 13 Several studies have reported that b-arrestins are also involved in heterologous desensitization of certain types of cell surface receptors, such as a 2 adrenergic receptor, metabotropic glutamate receptor, and lysophosphatidic acid receptor. [14] [15] [16] Yet, compared to homologous desensitization of bAR, 9 the roles of b-arrestins in heterologous desensitization of cardiac bAR signal, especially those triggered by activation of other GPCRs, are still poorly understood. Moreover, it is not clear how the heterologous desensitization of cardiac bAR induced by other GPCRs affects excitationcontraction coupling in cardiomyocytes.
In our previous study, we have shown that PDE4 is crucial in prostaglandin E2 (PGE2)-induced heterologous desensitization of cardiac bAR signalling. 17 Notably, the cross talk between EP-R and bAR is b 2 AR dependent, as the inhibitory effect of PGE2 on bAR signalling is absent in b 2 AR knockout cardiomyocytes, implying the important role of b 2 AR in coordination and integration of diversified signal pathways. 17 In the current study, we focused on understanding molecular events on b 2 AR that are involved in the heterologous cross talk. Meanwhile, we extended our exploration to the cross talk between several GPCRs and cardiac bARs. Our results reveal that some G s -and G q -coupled receptors, but not G i -coupled receptors promote phosphorylation of b 2 ARs via PKA and PKC, respectively. Heterologous phosphorylation of b 2 AR has minimal to small effect on bAR agonist-induced receptor active conformation for G s -coupling and receptor trafficking, but significantly promotes recruitment of PDE4D to phosphorylated b 2 AR in a b-arrestin 2-dependent manner. The b 2 AR/PDE4D complex effectively suppresses subsequent bAR agonist-induced cAMP/PKA signal. Consequently, it efficiently blocks bAR agonist-induced PKA phosphorylation of phospholamban (PLB), a critical protein involved in the regulation of myocyte calcium cycling, as well as impairs myocyte contractile response to b-adrenergic stimulation. Our data offer a general mechanism to understand how other GPCR signals intercept b-adrenergic regulation in cardiomyocytes, which may compromise cardiac function under pathophysiological conditions. 20 All experiments using PDE4D KO mice were carried out according to the European Community guiding principles in the Care and Use of Animals (2010/63/UE, 22 September 2010), the local Ethics Committee (CREEA Ile-de-France Sud) guidelines, and the French decree no. 2013-118, 1 February 2013 on the protection of animals used for scientific purposes (JORF no. 0032, 7 February 2013, p2199, text no. 24). Authorizations to perform animal experiments according to this decree were obtained from the Ministère français de l'Agriculture, de l'Agroalimentaire et de la Forêt (agreement no. B 92-019-01). Generation of Pde4d homozygous null mice has been described previously. 21 Ventricular myocytes were obtained from 8-to 10-week-old males as previously described. 22 Animals were anesthetized by intraperitoneal injection of pentothal (150 mg/kg), and the heart was quickly removed and placed into a cold Ca 2þ -free Tyrode's solution containing 113 mM NaCl, 4.7 mM KCl, 4 mM MgSO4, 0.6 mM KH 2 PO4, 0.6 mM NaH 2 PO4, 10 mM butanedione monoxime (BDM), 1.6 mM NaHCO3, 10 mM HEPES, 30 mM Taurine, and 20 mM D-glucose, adjusted to pH 7. 4 . The ascending aorta was cannulated and the heart was perfused with oxygenated Ca 2þ -free Tyrode's solution at 37 C for 4 min using retrograde Langendorff perfusion. For enzymatic dissociation, the heart was perfused with Ca 2þ -free Tyrode's solution containing Liberase TM Research Grade (Roche Diagnostics) for 10 min at 37 C. Then the heart was removed and placed into a dish containing Tyrode's solution supplemented with 0.2 mM CaCl 2 and 5 mg/mL BSA (Sigma-Aldrich). The ventricles were separated from the atria, cut into small pieces, and triturated with a pipette to disperse the Hormone inhibits cardiac bAR signal myocytes. Ventricular myocytes were filtered on gauze and allowed to sediment by gravity for 10 min. The supernatant was removed and cells were suspended in Tyrode's solution supplemented with 0.5 mM CaCl 2 and 5 mg/mL BSA. The procedure was repeated once and cells were suspended in Tyrode's solution with 1 mM CaCl 2 . Freshly isolated ventricular myocytes were plated in 35-mm culture dishes coated with laminin (10 lg/mL) and stored at room temperature until use. All experiments were performed at room temperature. Isolated cardiomyocytes were loaded with 1 lM Fura-2 AM (Thermo Fischer Scientific) at room temperature for 10 min. The loaded cells were field stimulated (5 V, 4 ms) at a frequency of 1 Hz. Sarcomere length and Fura-2 ratio (measured at 512 nm upon excitation at 340 nm and 380 nm) were simultaneously recorded using an IonOptix System (IonOptix). Cell contractility was assessed by the percentage of sarcomere shortening, which is the ratio of twitch amplitude (difference of end-diastolic and peak systolic sarcomere length) to end-diastolic sarcomere length. Ca 2þ transients were assessed by the percentage of variation of the Fura-2 ratio by dividing the twitch amplitude (difference of end-diastolic and peak systolic ratios) to enddiastolic ratio. The t1/2off (s) was used as an index of relaxation and Ca 2þ transient decay kinetics. All parameters were calculated offline using a dedicated software (IonWizard).
Adenovirus infection
Adult ventricular cardiomyocytes were cultured in 6-well plates in minimum essential medium with 10% 2,3-BDM. Neonatal ventricular cardiomyocytes were cultured in 24-well plates with coated coverslips in Dulbecco's modified Eagle's media containing 10% bovine fetal serum.
The recombinant adenovirus encoding flag-b 2 AR, flag-b 2 AR-PKA4A mutant (flag-b 2 AR with point mutations of serine residues at 261, 262, 345, 346 to alanine), HA-tagged mouse b 1 AR, GFP-N-terminal-PDE4D5 and mCherry-tagged PDE4D5 were generated with the pAdEasy system (Qbiogene, Carlsbad, CA). PM-ICUE3 and ICUE3 and SR-AKAR fluorescent resonance energy transfer (FRET) biosensor adenoviruses are generated in our lab. 23 Cells were infected for 2 h for neonatal cardiomyocytes and 24 h for adult cardiomyocytes, media were then removed and replaced with fresh media. All experiments were carried out after 48 h after virus infection.
Immunoprecipitation, co-immunoprecipitation, and western blotting
Ventricular cardiac cardiomyocytes were cultured in 6-well plates for 48 h. After addition of different agonists, cells were then harvested in lysis buffer (25 mM Hepes, pH 7.4, 5 mM EDTA, 150 mM NaCl, 0.5% Triton X-100, and protease inhibitors containing 2 mM Na 3 VO 4 , 1 mM PMSF, 10 mM NaF, 10 mg/mL Aprotinin, 5 mM Bestatin, 10 mg/mL Leupeptin, and 2 mg/ mL Pepstain A). After stimulation, cardiomyocytes were spun down using bench-top centrifuge machine at top speed for 30 s, supernatant was quickly removed and cell pellets were lysed using lysis buffer described above. Same amount of protein (20 mg) was resolved on SDS-PAGE gels and later detected with anti-phospho-PLB (serine 16) antibody (Badrilla, Leeds, United Kingdom). All primary antibodies were revealed with IRDye 800 CW goat secondary antibodies using Odyssey detection system (Li-cor Biosciences, Lincoln, Nebraska). The optical density of the bands was analysed with NIH Image J software.
Confocal imaging
The confocal imaging was carried out on Zeiss LSM 700 Axio Observer confocal microscope (Oberkochen, Germany) using a Zeiss PlanApochromat 63 Â/1.4 oil objective. Neonatal cardiomyocytes were cultured in 24-well plates with coverslips and infected with flag-b 2 AR and Nb80-GFP adenovirus. After stimulation, cardiomyocytes were fixed with phosphate-buffered saline (PBS) containing 4% paraformaldehyde at room temperature and then blocked with PBS containing 0.2% Nonidet P-40 and 2% goat serum followed by staining with anti-flag antibody (mouse monoclonal IgG2b, Sigma, St. Louis, MO). The primary antibody was labelled with Alexa Fluor 594 labelled goat anti-mouse IgG antibody (Life Technologies, Carlsbad, CA) and images were collected using 488 nm and 555 nm laser lines for excitation, respectively. Images were processed and analysed with Zen Software from Zeiss (Oberkochen, Germany).
FRET assay
Neonatal cardiomyocytes infected with PM-ICUE3, ICUE3 or SR-AKAR3 biosensor were maintained in PBS during FRET recording as described previously. 24 Images were acquired with a Leica DMI 3000B microscope with a 40 Â/1.3 NA oil-immersion objective lens. FRET images acquisition setting and FRET intensity measurement were carried out as previously described. 17 
Data analysis
All bar graphs with scatter plots were show as mean ± standard error of the mean of at least three independent experiments. One-way analysis of variance (ANOVA) with Dunnett's multiple comparison test or student's unpaired t-test was performed using the GraphPad Prism 7 software (GraphPad Inc., San Diego, CA) to determine statistical significance as follows: n.s, not significant; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; or #P < 0.05; ##P < 0.01; ###P < 0.001; ####P < 0.0001. 
Results

Different hormones/GPCR agonists promote PKA/PKC phosphorylation of bAR in adult rat ventricular cardiomyocytes
We first examined the effect of several neurohormonal stimuli/GPCR agonists on phosphorylation of b 2 AR at putative PKA phosphorylation sites, a well-known b-adrenergic stimuli-induced post-translational modification that promotes desensitization of b 2 AR. 25 Adult rat ventricular cardiomyocytes expressing flag-b 2 AR were stimulated with the bAR agonist isoproterenol (ISO, 1 mM) or a set of different GPCR agonists, including G s -coupled receptors: prostaglandin E 2 receptor (EP-R) agonist prostaglandin E 2 (PGE2), b 1 AR agonist dobutamine, dopamine receptor agonist dopamine, corticotropin releasing factor type 2 receptor agonist urocortin, relaxin receptor agonist relaxin and adenosine receptor agonist adenosine; G q -coupled receptors: a adrenergic receptor (a 1 AR) agonist phenylephrine, angiotensin receptor type I (AT1R) agonist angiotensin II (Ang II) and protease-activated receptors agonist thrombin; and G i -coupled a 2 adrenergic receptor (a 2 AR) agonist clonidine. Stimulation with PGE2, dopamine, urocortin, relaxin, adenosine, phenylephrine, or Ang II significantly enhances the phosphorylation of b 2 AR at putative PKA phosphorylation sites ( Figure 1A ), which is similar to bAR agonist ISO. In contrast, stimulation with dobutamine, thrombin, or clonidine has either no effect or minimal effect. In addition, we show that b 1 AR is subjected to a similar influence by the tested GPCR agonists, except that urocortin has no significant effect on b 1 AR phosphorylation, but b 1 AR selective agonist dobutamine does (see Supplementary material online, Figure S1 ). Besides PKA, the putative PKA phosphorylation sites can also be phosphorylated by other kinases including PKC. 25 Application of PKA selective peptide inhibitor PKI effectively diminishes ISO-, PGE2-, phenylephrine-, and dopamine-induced phosphorylation of b 2 AR ( Figure 1C ). In contrast, the PKC inhibitor GO6976 selectively inhibits dopamine-and phenylephrine-induced b 2 AR phosphorylation ( Figure 1B) . The inhibitory effect of PKI on phenylephrine-induced phosphorylation of b 2 AR is probably due to non-selective inhibition of PKC by high concentration of PKI (10 mM) or activation of the bAR-PKA cascade by phenylephrine at high concentrations.
26,27
Different hormones/GPCR agonists inhibit b-adrenergic stimulation induced adult cardiomyocyte contractile response
We then examined whether heterologous phosphorylation of bAR leads to desensitization of cardiac b-adrenergic signal in native rat ventricular cardiomyocytes. Stimulation of bAR agonist ISO (100 nM) promotes robust increases in myocyte contractile shortening ( Figure 2A and L). While pretreatment with PGE2, Ang II, dopamine, or phenylephrine alone has no effect on resting sarcomere lengths (see Supplementary material online, Figure S2A ), it significantly inhibits b-adrenergic stimulation-induced contractile shortening responses ( Figure 2B -E and L). In parallel, these GPCR stimuli significantly diminishes calcium transient amplitudes and prolongs recovery tau in response to b-adrenergic stimulation ( Figure 2F -J,M, and N), indicating impaired calcium handling for contractile function after pretreatment with these GPCR agonists. Consistently, pretreatment of cardiomyocytes with PGE2, Ang II, dopamine, or phenylephrine significantly inhibits b-adrenergic-induced PKA phosphorylation of PLB at serine 16 site ( Figure 2K) , an essential event involved in regulating myocyte calcium cycling and contractile function. In addition, phosphorylation of other PKA targets in response to ISO stimulation, such as cardiac Troponin I, is also inhibited by pretreatment with Ang II, dopamine or phenylephrine, but not by PGE2 (see Supplementary material online, Figure S2C ), suggesting divergent inhibition of local PKA activity in response to b-adrenergic stimulation after various GPCR agonists pretreatment. Figure 1 Activation of different GPCRs promotes phosphorylation of b 2 AR in adult ventricular cardiomyocytes. Adult rat ventricular cardiomyocytes expressing flag-b 2 AR were cultured for 48 h before stimulation with different GPCR agonists as indicated (1 mM for 5min, respectively). The flag-b 2 AR was immunoprecipitated using anti-FLAG beads. The elution was subjected to western blot to detect b 2 AR phosphorylation. The phosphorylation of b 2 AR at putative PKA phosphorylation sites is quantified and expressed as fold over non-stimulated group (Control). Data are obtained from 3-7 independent experiments and shown as mean ± S.E.M. n.s, not significant; *P < _ 0.05; **P < _ 0.01; ***P < _ 0.001 (vs. Control group) by student's unpaired t-test. ISO, isoproterenol; PGE2, Prostaglandin E2; Dobu, Dobutamine; Dopa, Dopamine; Phe, Phenylephrine; Ang II, Angiotensin II. Adult rat ventricular cardiomyocytes expressing flag-b 2 AR were pretreated with 1 mM of PKC inhibitor GO6976 (B) or 10 mM of PKA peptide inhibitor PKI (C) for 30 min followed by stimulation with different GPCR agonists as indicated (1 mM for 5 min, respectively). Flag-b 2 AR was immunoprecipitated using anti-FLAG beads. Phosphorylated b 2 AR at putative PKA phosphorylation sites and total b 2 AR were detected by western blot. Data represent 3-5 independent experiments.
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Phosphorylation of b 2 AR at PKA sites does not affect bAR agonist-induced receptor activation
Phosphorylation of bARs at PKA sites can affect receptor signalling via modulation of either receptor-G protein coupling to inhibit adenylyl cyclase-dependent cAMP synthesis 28 or receptor-associated phosphodiesterase 4 (PDE4)-dependent cAMP hydrolysis. 29, 30 Notably, the cross talk between EP-R and bARs is b 2 AR dependent. 17 Thus we used PGE2 and b 2 AR as an example to further explore the underlying mechanism of heterologous desensitization of b-adrenergic signal and impairment of contractile function. We first applied a set of conformation-specific camelid single-domain nanobodies (Nbs): Nb80 and Nb37 to examine activation of b 2 AR and G s protein, respectively. [31] [32] [33] Nb80, an indicator of active receptor conformation, selectively binds agonist-occupied b 2 AR. In cardiomyocytes, while bAR agonist ISO stimulation significantly induces recruitment of Nb80 to b 2 AR on the plasma membrane, PGE2 fails to do so ( Figure 3) . However, PGE2 pretreatment does not prevent recruitment of Nb80 to b 2 AR on the plasma membrane upon subsequent stimulation with ISO ( Figure 3 ). This phenomenon is also preserved in HEK293 cells (see Supplementary material online, Figure S3A ).
The association of Nb80 to b 2 AR is confirmed by coimmunoprecipitation (see Supplementary material online, Figure S3B and D), suggesting that PKA phosphorylation of b 2 AR does not influence agonist-induced receptor activation. Meanwhile, Nb37 specifically recognizes the guanine-nucleotide-free form of Ga s representing the catalytic intermediate of G protein activation. 34 While PGE2 is incapable of recruit Nb37 to b 2 AR, after PGE2 pretreatment, ISO still effectively promotes b 2 AR and Nb37 association with a small reduction when compared to those induced by ISO directly (see Supplementary material online, Figure S3C and E). In comparison, the myocyte contractile response to ISO stimulation is completely abolished after PGE2 pretreatment ( Figure 2L ), indicating the existence of additional regulation components besides reduction of b 2 AR coupling to G s .
3.4 PKA phosphorylation of b 2 AR promotes assembly of b 2 AR/PDE4D complex at the plasma membrane to promote desensitization of b adrenergic signalling
We then examined the potential role of PDE in hormone-induced inhibitory effect on bAR signal. In isolated adult rat ventricular cardiomyocytes, PGE2 promotes significant association of b 2 AR with PDE4D5 ( Figure 4B and C), in a fashion similar to the b 2 AR/PDE4D5 complex formation induced by bAR agonist ISO. 29, 30 However, unlike bAR agonist ISO, which could induce receptor endocytosis, PGE2 stimulation fails to induce b 2 AR internalization (see Supplementary material online, Figure  S3F and G). Accordingly, PGE2 stimulation promotes significant recruitment of PDE4D5 to b 2 AR in the plasma membrane fraction (see Supplementary material online, Figure S3I ), suggesting that PDE4D and b 2 AR form a complex on the cell surface. Moreover, mutation of PKA phosphorylation sites on the b 2 AR abolishes the PGE2-induced binding of b 2 AR with PDE4D5 ( Figure 4C ). In addition, PGE2, phenylephrine, and Ang II, but not adenosine promote PDE4D phosphorylation at putative PKA phosphorylation sites ( Figure 4A and see Supplementary material online, Figure S3H ), which increases enzymatic activity to attenuate bAR signalling. 35 We then assessed whether inhibition of PDE4D is able to rescue the desensitized b-adrenergic signal on the plasma membrane. We took advantage of a FRET-based cAMP biosensor, which is selectively targeted to the plasma membrane (PM-ICUE3). 36 In WT neonatal cardiomyocytes, bAR agonist ISO induces robust cAMP signal across the plasma membrane ( Figure 5A and G). Pretreatment with PGE2 blunts ISO (1 lM)-induced cAMP signal ( Figure 5B and G) . At a concentration when applying alone has no effect on cAMP and PKA signal (data not shown and ref. 17 ), PDE4 inhibitor rolipram significantly rescues b-adrenergic stimulation-induced cAMP signal dampened by PGE2 pretreatment (Figure 5D-G) . To avoid the potential saturation of FRET biosensor induced by 1 lM of ISO, a submaximal concentration of ISO (10 nM) was used. Stimulation with ISO (10 nM) generates a moderate cAMP signal that can be further enhanced by addition of forskolin (50 mM) and IBMX (100 mM); and the modest increase in cAMP induced by ISO is also blunted by PGE2 pretreatment ( Figure 5H) . However, addition of a submaximal concentration (100 nM) of rolipram significantly restores ISOinduced cAMP signal in PGE2 pretreatment group ( Figure 5H) . At both saturated (1 lM) and submaximal (10 nM) concentration of ISO, the rolipram-induced recoveries in cAMP signal in the PGE2-pretreated groups are still slightly below the control groups without PGE2 treatment, respectively ( Figure 5G and H). These data indicate that PGE2 induces a significant yet small impairment of the b 2 AR-Gs coupling. We also measured global cAMP levels in cardiomyocytes with another FRET biosensor ICUE3. Similar to those observed on the plasma membrane, ISO-induced cAMP signal in the whole cells is inhibited by PGE2 pretreatment, which is also rescued by rolipram (see Supplementary material online, Figure S4 ). Together, these data suggest that PGE2-induced of activation and recruitment of PDE4D to the plasma membrane effectively metabolizes the bAR-induced cAMP at both the plasma membrane and in the cytoplasm.
We further validated the functional involvement of PDE4D in GPCR signal cross talk using cardiomyocyte contractile shortening assay. In WT cardiomyocytes, stimulation with bAR agonist ISO greatly increases myocyte contractile shortening ( Figure 5I and see Supplementary material online, Figure S5A ), and pretreatment with PGE2 significantly inhibits ISO-induced contractile shortening response ( Figure 5I and see Supplementary material online, Figure S5B ). In parallel, PGE2 pretreatment reduces calcium transient amplitude and prolongs calcium decay tau in response to b-adrenergic stimulation, indicating impaired calcium handling for contractile function ( Figure 5J , K, and see Supplementary material online, Figure S5C and D). Compared to general bAR stimulation, stimulation of b 2 AR (revealed by in the presence of b 1 AR selective antagonist CGP20712A) induces small but significant increases in the contractility and intracellular calcium transient, respectively (see Supplementary material online, Figure S6A and B and refs. 37, 38 ). PGE2 pretreatment inhibits b 2 AR stimulation-induced increases in contractile shortening and calcium transient. Addition of rolipram (100 nM) rescues both contractile shortening and calcium transient amplitude in PGE2 pretreatment groups (see Supplementary material online, Figure S6A and B). In contrast, deletion of PDE4D rescues ISO-induced contractile response in cardiomyocytes pretreated with PGE2 ( Figure 5I and see Supplementary material online, Figure S5E and F). Ablation of PDE4D, to a large extent, also restores calcium transient amplitude and decay tau in response to b-adrenergic stimulation ( Figure 5J , K, and see Supplementary material online, Figure S5G and H). Together, these results suggest that PDE4 negates bAR responses during heterologous cross talks. 
b-arrestin 2 is required for PDE4-mediated desensitization of b-adrenergic signal
We have recently shown that PGE2 is able to attenuate bAR stimulated cardiac contractility in mouse hearts by preventing cAMP propagation into the sarcoplasmic reticulum (SR), a critical organelle for calcium cycling and EC coupling. 17 Thus, we further assessed the role of GPCR cross talk on b adrenergic stimuli-induced PKA activity at the SR by applying a FRET-based biosensor, SR-AKAR3. 23 In WT neonatal cardiomyocytes, PGE2 significantly attenuates ISO-induced PKA activity at the SR (Figure 6A , B, G, and see Supplementary material online, Figure S7A , B, After stimulation with 1 mM PGE2 or 1 mM Angiotensin II (Ang II) for 5 min, cardiomyocytes were lysed and b 2 AR was immunoprecipitated using anti-FLAG M2 beads. The elution was subjected to western blot to detect b 2 AR and PDE4D5, respectively. The PDE4D5 levels are quantified and expressed as fold over b 2 AR levels in corresponding non-stimulated groups. In (B) and (C), data are obtained from four independent experiments and shown as mean ± S.E.M. Between paired groups, n.s, not significant; *P < 0.05 by student's unpaired t-test. The percent shortening in adult WT or PDE4D KO mouse ventricular cardiomyocyte sarcomere length (I), the amplitude of calcium release (calcium transient) (J) and the rate of calcium decay (s) (K) are shown in bar graph with scatter plots. In (I-K), data are obtained from three independent experiments and shown as mean ± S.E.M. Between paired groups, n.s, not significant; *P < _ 0.05; **P < _ 0.01; ***P < _ 0.001; ****P < _ 0.0001 by student's unpaired t-test. Between paired groups, n.s, not significant; ***P < _ 0.001; ****P < _ 0.0001 by student's unpaired t-test. The percent shortening in adult WT or b-arrestin 2 KO mouse ventricular cardiomyocyte sarcomere length (H), the amplitude of calcium release (calcium transient) (I) and the rate of calcium decay (s) ( J) are shown in bar graph with scatter plots. In (H-J), data are obtained from three independent experiments and shown as mean ± S.E.M. Between paired groups, *P < _ 0.05; **P < _ 0.01; ****P < _ 0.0001 by student's unpaired t-test.
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and E). Mutation of PKA phosphorylation sites of b 2 AR abolishes this inhibitory effect (see Supplementary material online, Figure S7C-E) . Meanwhile, studies show that ISO induced association of PDE4D and b 2 AR is dependent on b-arrestin 2. 13, 30 Here, the PGE2-induced association between b 2 AR and PDE4D5 is absent in the cardiomyocytes lacking b-arrestin 2 ( Figure 4B) , confirming a scaffold role of b-arrestin 2 in connecting PDE4D to the b 2 AR after PGE2 stimulation. We thus examined the roles of b-arrestin 2 in the observed cross talk between the tested GPCRs and b 2 AR in cardiomyocytes. Deletion of b-arrestin 2, but not b-arrestin 1 abolishes the PGE2 inhibitory effect on ISO-induced PKA activity at the SR ( Figure 6C-G) . While PKA-mediated phosphorylation of b 2 AR is involved in promoting receptor coupling to G i , 39 pretreatment with G i inhibitor pertussis toxin does not affect the inhibitory effect of PGE2 on ISO-induced PKA activity at the SR (see Supplementary material online, Figure S7F ). We then further assessed the role of b-arrestin 2 in receptor cross talk-dependent modulation of cardiomyocytes contractile function. In WT mouse ventricular cardiomyocytes, bAR agonist ISO stimulation significantly enhances myocyte contractile shortening ( Figure 6H and see Supplementary material online, Figure S8A ), pretreatment with PGE2 blunts the contractile response ( Figure 6H and see Supplementary material online, Figure S8B ). In parallel, PGE2 pretreatment decreases calcium transient amplitudes and prolongs calcium decay tau in response to b-adrenergic stimulation ( Figure 6I , J and see Supplementary material online, Figure S8F and G). In contrast, deletion of b-arrestin 2 rescues ISOinduced contractile response as well as calcium transient amplitude and recovery tau in cardiomyocytes pretreated with PGE2 ( Figure 6H -J and see Supplementary material online, Figure S9A , B, F, and G). Together, our data suggest that the PGE2-induced binding of b-arrestin 2 and PDE4D to b 2 AR effectively hydrolyzes cAMP produced by adenylyl cyclases in response b-adrenergic stimulation, contributing to desensitization of the bAR-PKA signalling in cardiomyocytes.
b-arrestin 2 serves as a nexus to coordinate PDE4-dependent desensitization of b-adrenergic signal by different GPCRs stimulations
We further examined whether other GPCRs utilize the same machinery to cross talk to b 2 AR. Ang II or phenylephrine alone does not affect PKA activity at the SR, but significantly blunts ISO-induced PKA activity at the SR (see Supplementary material online, Figure S10A and B). While Ang II promotes phosphorylation of PDE4D and recruitment of PDE4D to the phosphorylated b 2 AR, deletion of the b 2 AR PKA sites abolishes the recruitment of PDE4D to receptors ( Figure 4A and C) . Accordingly, PDE4 inhibitor rolipram to a great extent rescues the b-adrenergic-stimulation-induced PKA activity after pretreatment with Ang II or phenylephrine (see Supplementary material online, Figure S10A ). In addition, pretreatment with PKC inhibitor GO6976 abolishes the inhibitory effects of Ang II and phenylephrine on b-adrenergic-stimulation induced PKA activity at the SR (see Supplementary material online, Figure S10B ), confirming the involvement of PKC in the cross talk between these G qcoupled receptors and b 2 AR in cardiomyocytes.
Similar to PGE2, Ang II, dopamine or phenylephrine significantly blunts ISO-induced PKA phosphorylation of PLB at serine 16 site in WT mouse cardiomyocytes ( Figure 7A) . These GPCR stimuli also inhibit myocyte contractile response and calcium transient amplitudes and decay tau to b-adrenergic stimulation ( Figure 7B -D and see Supplementary material online, Figure S8C-E and H-J) . However, deletion of b-arrestin 2 rescues ISO-induced PKA phosphorylation of PLB and myocyte contractile response in cardiomyocytes pretreated with dopamine or phenylephrine, and to a lesser extent recovers the responses in the cells pretreated with Ang II (Figure 7E , F, and see Supplementary material online, Figure  S9C -E). Similarly, deletion of b-arrestin 2 also rescues calcium transient amplitude and decay tau in response to b-adrenergic stimulation in cardiomyocytes pretreated with dopamine or phenylephrine, yet lesser effect on those treated with Ang II (Figure 7G , H, and see Supplementary material online, Figure S9H-J) . Together, these data suggest a general mechanism of cardiac bAR desensitization promoted by other GPCRs via recruitment of PDE4D to PKA/PKC phosphorylated bARs in a b-arrestin 2-dependent manner, which inhibits adrenergic signalling by increasing cAMP hydrolysis (Figure 8 ).
Discussion
It is well known that bAR signalling undergoes sophisticated modulation by an increasing number of factors, including homologous desensitization 1, 40 and heterologous desensitization. 28 Here, we reveal that some G s -and G q -coupled receptors promote bAR phosphorylation at putative PKA phosphorylation sites through activation of PKA and PKC, respectively ( Figure 1 and see Supplementary material online, Figure S1 ). The phosphorylation of b 2 AR had small impact on bAR agonist ISOinduced receptor-G-protein coupling without influence on receptor internalization. Further evidence shows that phosphorylated b 2 AR promotes b-arrestin 2-dependent recruitment of active PDE4 isoform to the receptors at the plasma membrane, which effectively hydrolyzes cAMP generated by subsequent application of bAR agonist ISO. Genetic deletion of PDE4D or b-arrestin 2 and pharmacological inhibition of PDE4D abolish the inhibitory effects of other GPCRs on bAR-induced contractile responses. Together, this study reveals a general mechanism for desensitization of cardiac bAR signalling by other G s -and G q -coupled receptors, which is in contrast to the inhibitory effect of G i -coupled muscarinic receptors on bAR signal via inhibition of adenylyl cyclase for cAMP production. 41 Traditionally, GPCR desensitization is attributed to the diminished coupling between phosphorylated receptors to G proteins. In agreement, using novel biosensors, the PKA-phosphorylated b 2 AR induced by PGE2 pretreatment displays a significant reduction in binding to G s proteins in response to ISO stimulation, but without alteration in binding to Nb80, a nanobody selectively binding to ISO-induced receptor active conformation (see Supplementary material online, Figure S3B and C). This reduced receptor-G s coupling has a small impact on bAR agonistinduced cAMP signal ( Figure 5G and H) . In comparison, the inhibitory effect of PGE2 on bAR signal appears to be due primarily to an enhanced hydrolysis of cAMP mediated by receptor-associated PDE4Ds. Disruption of b 2 AR-PDE4D complex or inhibition of PDE4 abolishes the inhibition of PGE2 on ISO-induced cAMP signal in cardiomyocytes. Classic literature and crystal structure studies suggest that G protein and arrestin potentially share a common GPCR-binding interface, [42] [43] [44] which means their binding to b 2 AR would be mutually exclusive. The observations in this study suggest that PKA phosphorylation of b 2 AR unlikely switch receptor from Gs-coupling to arrestin binding completely, therefore resulting into a reduced binding to Gs while gaining increase in arrestin binding. Alternatively, there could be existence of a tertiary complex between receptor, G s , and arrestin, as suggested by a recent co-crystallography study. 45 Moreover, there may be different pools of Among cardiac bARs, b 1 AR is the primary subtype that mediates cardiac contractile response whereas stimulation of b 2 AR promotes small increases in cardiac contractility. However, b 2 AR appears to be essential to mediate cross talk between EP-R and bAR since deletion of b 2 AR completely abolishes the inhibition of PGE2 on b 1 AR signal in cardiac myocytes. 17 In contrast, deletion of b 1 AR does not affect the inhibitory effect of PGE2 on b 2 AR signal. 17 This apparent paradox is further explored in the current study. While PGE2 stimulation promotes PKA phosphorylation on both b 1 AR and b 2 AR, they seem to induce opposite modulation of the receptor association with PDE4D in cardiac myocytes. Agonist stimulation of b 2 AR promotes arrestin-dependent binding of PDE4Ds to the activated receptor. 46 In agreement, we show that PGE2
promotes PKA phosphorylation-dependent and arrestin-mediated recruitment of PDE4D to the b 2 AR on the plasma membrane ( Figure 4B , C, and see Supplementary material online, Figure S3I ). This preassembled b 2 AR-PDE4D complex effectively attenuates signal induced by bAR agonist ISO (see Supplementary material online, Figure S6 and ref. 46 ). In contrast, PDE4D binds to b 1 AR at the baseline, 47 which undergoes dissociation upon stimulation with bAR agonist ISO. 46 Pretreatment with PGE2 however abolishes ISO-induced dissociation of PDE4 from b 1 AR, contributing to inhibition of b 1 AR in cardiomyocytes. 17 Interestingly, this inhibitory effect of PGE2 on b 1 AR signal is absent in b 2 AR-KO myocytes, supporting a necessary role of b 2 AR in the process. 17 Together, the cross talk between PGE2 and b 2 AR is sufficient to inhibit cAMP signalling and attenuate contractile responses induced by general bAR stimulation WT myocytes. The mechanism underlying the inhibitory effect of PGE2 on dissociation of b 1 AR-PDE4 complex is currently unclear; a possible role of b 2 AR and/or PGE2-induced PKA phosphorylation of b 1 AR in this process remain to be examined. Agonist-induced homologous desensitization of b 2 AR is primarily dependent on GRK-mediated receptor phosphorylation and GRK phosphorylation-dependent b-arrestin binding. 48, 49 GPCRs usually possess multiple GRK phosphorylation sites that can be phosphorylated in a tissue-, cell-, or agonist-dependent manner, which has recently been postulated to create a 'phosphorylation barcode' that offers a way to regulate divergent signalling and trafficking of GPCRs. 50 This notion could explain how the pattern of receptor phosphorylation determines the receptor conformation of binding to b-arrestins and its functional capabilities. 50, 51 Here, we observe an increased association between b 2 AR, b-arrestin 2, and PDE4D in a PKA phosphorylation-dependent manner after stimulation of EP-R by PGE2 or AT1R by Ang II. However, the PGE2 stimulation does not promote receptor internalization, which is different from bAR agonist ISO-induced b-arrestin 2-mediated receptor endocytosis in a GRK phosphorylation-dependent manner 48, 49 . This observation is in line with previous reports showing that recruitment of b-arrestin 2 alone is not sufficient for initiating receptor internalization, 52 and additional regulators such as GRK and PI3K are necessary for promoting receptor endocytosis. 53 Meanwhile, GRKs can also participate in heterologous desensitization of cardiac bARs by activation of tumour necrosis factor receptors, 54 insulin receptors 19 or vasopressin receptors. 55 Together, agonist occupancy in combination with receptor phosphorylation by PKA or GRK may offer different structural interface to interact signalling molecules. These observations essentially expand the 'barcode' regulation from GRKs to a broad range of kinases including PKA and PKC, revealing the complexity in the regulation of GPCR activity and trafficking under homologous and heterologous stimuli.
In the current study, why stimulation with some G s -and G q -coupled receptor agonists but not others promotes phosphorylation of b 2 AR is currently unclear; the subcellular distribution of the receptors likely plays a key role. In the case of G s -coupled receptors, both relaxin and urocortin effectively promote cardiac contraction, 56, 57 but PGE2 fails to do so.
In contrast, PGE2-induced cAMP diffuses into lipid rafts, 36 a membrane microdomain containing b 2 AR. These observations argue that relaxin and urocortin induce segregated intracellular signals from those induced by PGE2. On the other hand, stimulation of either a 1 adrenergic receptor by phenylephrine or angiotensin II type 1 receptor by Ang II are known to promote myocyte contractility 58, 59 ; these stimuli also promote b 2 AR phosphorylation ( Figure 1) . In comparison, thrombin is not known to promote myocyte contractility; and it fails to promote b 2 AR phosphorylation. Therefore, the actions of a 1 adrenergic receptor and angiotensin II type I receptor activation on myocyte contractility may be converged with or relevant to b-adrenergic signal. Meanwhile, angiotensin II type I receptor may use a b-arrestin-dependent mechanism to promote contractility independent of b-adrenergic signal. 60 Together, these observations suggest that different GPCRs are spatially and functionally segregated to fine-tune their functional roles in cardiomyocytes. In addition, despite that both b-arrestin 2 and b-arrestin 1 are capable of binding to bARs and PDE4, 13 we observe a selective role of b-arrestin 2 in the desensitization of bAR after heterologous GPCR activation. This selectivity could fine-tune cross talk between GPCRs and bARs for local subcellular signalling, which may be further modulated by biased ligands and/or hetero-oligomeric status of GPCRs in cardiomyocytes. 61, 62 Our data indicate that PKC is involved in phenylephrine/Ang II induced-b 2 AR phosphorylation ( Figure 1B and see Supplementary material online, Figure S10B ). In line with these observations, phenylephrine/ Ang II also promotes PDE4D phosphorylation ( Figure 4A) . The antibody 
that detects putative PKA phosphorylation sites of PDE4D (pPDE4D S190) has been used extensively in the field to detect phosphorylation of PDE4D. 17, [63] [64] [65] [66] Here, we further validated the antibody specificity with tissues from WT and PDE4D-/-mouse hearts by western blots. The result shows that PDE4D-/-heart tissue display significantly reduced phosphorylation in the pPDE4DS190 antibody detection (see Supplementary material online, Figure S3H ). The remaining signal in PDE4D-/-tissues is probably due to the expression of PDE4A and PDE4B proteins, which share high-sequence homologue to the PDE4D. Together, these data in Figure 4A indicate that PKC is capable to induce phosphorylation of PDE4D in animal hearts.
Under clinical conditions such as congestive heart failure or hypertrophy, many neuronal hormones and cytokines such as PGE2 67, 68 and Ang II 69, 70 are evaluated. Our study reveals a general mechanism that b-arrestin 2 and PDE4D act as essential mediators in heterologous desensitization of bARs by other GPCR stimuli, which effectively block b-adrenergic-induced PKA phosphorylation of PLB and myocyte contractility. This happens in a manner depending on the phosphorylation of b 2 AR at putative PKA phosphorylation sites. Meanwhile, the expression, activity, and subcellular distribution of PDE4/PDE4D are depending on the stage of pathological development, [71] [72] [73] which could further contribute to divergent modulation of cardiac adrenergic signalling. Together, this study expands the complexity on the regulation of cardiac bAR signal under elevated neurohormonal stimuli, which may contribute to the development of pathophysiological conditions such as heart failure.
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